medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2009, Number 2

<< Back Next >>

Ann Hepatol 2009; 8 (2)

Common SPINK-1 mutations do not predispose to the development of non-alcoholic fatty liver disease

Oruc N, Ozutemiz O, Salih AU, Berdeli A, Ersoz G, Gunsar F, Karasu Z, Ilter T, Batur Y

Language: English
References: 19
Page: 116-119
PDF size: 106.70 Kb.


Text Extraction

Background: Non-alcoholic fatty liver disease (NAFLD) is common in obese and diabetics. Serine protease inhibitor Kazal-1 (SPINK-1) protein is highly expressed in the liver and adipose tissue of diabetic and obese suggesting its role in NAFLD. SPINK-1 also behaves as an acute phase reactant protein. Some genetic factors including the genetic variations in SPINK-1 protein have been linked to chronic pancreatitis and diabetes. We therefore hypothesized that SPINK-1 mutations might be a risk factor for the development of NAFLD. Methods: Liver biopsy proven fifty NAFLD cases (20 steatohepatitis, 30 diffuse fatty liver disease and 44 healthy controls were included to the study. Liver function tests were measured. Body mass index was calculated. Insulin resistance was determined by using a homeostasis model assessment (HOMA-IR). Ultrasound evaluation was performed for each subject. Common genetic mutations in the third exon of SPINK-1 gene were analyzed by direct sequencing method. Results: We found two cases with a SNP at N34S location in NAFLD group (allele frequency %4). One subject with diffuse fatty liver disease and other with liver cirrhosis due to NAFLD had N34S mutation. No SNPs were detected in healthy controls. In conclusions, in limited number of patients SPINK-1 mutations were not considered as a risk factor alone for NAFLD development.


REFERENCES

  1. Siebler J, Galle PR, Weber MM. The gut-liver-axis: endotoxemia, inflammation, insulin resistance and NASH. J Hepatol 2008; 48: 1032-4.

  2. Jiang J, Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord 2008; 6: 1-7.

  3. El-Zayadi AR. Hepatic steatosis: A benign disease or a silent killer. World J Gastroenterol 2008; 14(26): 4120-6.

  4. Schweitz H, Vincent JP, Lazdunski M. Trypsin—pancreatic secretory inhibitor (Kazal inhibitor) interaction. Kinetic and thermodynamic properties. Biochemistry 1973; 12: 2841-6.

  5. Masamune A, Kume K, Takagi Y, Kikuta K, Satoh K, Satoh A, Shimosegawa T. N34S mutation in the SPINK1 gene is not associated with alternative splicing. Pancreas 2007; 34: 423-8.

  6. Teich N, Mössner J. Hereditary chronic pancreatitis. Best Pract Res Clin Gastroenterol 2008; 22: 115-30.

  7. Behrman SW, Fowler ES. Pathophysiology of chronic pancreatitis. Surg Clin North Am 2007; 87: 1309-24.

  8. Schneider A, Suman A, Rossi L, Barmada MM, Beglinger C, Parvin S, Sattar S, et al. SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh. Gastroenterology 2002; 123: 1026-30.

  9. Hassan Z, Mohan V, Ali L, Allotey R, Barakat K, Faruque MO, Deepa R, et al. SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the Southern Indian sub-continent. Am J Hum Genet 2002; 71: 964-8.

  10. Jönsson P, Linder C, Genell S, Ohlsson K. Extrapancreatic origin of the pancreatic secretory trypsin inhibitor as an acute-phase reactant. Pancreas 1996; 12: 303-7.

  11. Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, Landt O, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000; 25: 213-6.

  12. Takamatsu S, Noguchi N, Kudoh A, Nakamura N, Kawamura T, Teramoto K, Igari T, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 609-14.

  13. Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 1162-9.

  14. Adibi A, Janghorbani M, Shayganfar S, Amini M. First-degree relatives of patients with type 2 diabetes mellitus and risk of non-alcoholic Fatty liver disease. Rev Diabet Stud 2007; 4: 236-41.

  15. Boden G. Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clin North Am 2001; 30: 801-15.

  16. Polonsky KS, Sturis J, Bell GL. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the P cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-83.

  17. Kido H, Yokogoshi Y, Katunuma N. A low-molecular-mass Kazal-type protease inhibitor isolated from rat hepatocytes is identical to rat pancreatic secretory trypsin inhibitor II. Purification and amino acid sequence. Eur J Biochem 1990; 188: 501-6.

  18. Ohmachi Y, Murata A, Matsuura N, Yasuda T, Yasuda T, Monden M, Mori T, et al. Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma. Int J Cancer 1993; 55: 728-34.

  19. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 2007; 43: 736-44.




2020     |     www.medigraphic.com